Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy (SAPPHIRE)

This study has been completed.
Sponsor:
Information provided by:
Cordis Corporation
ClinicalTrials.gov Identifier:
NCT00231270
First received: October 3, 2005
Last updated: April 17, 2008
Last verified: July 2007

October 3, 2005
April 17, 2008
August 2000
Not Provided
  • composite of major adverse clinical events including death, any stroke, and/or myocardial infarction at 30-days post-procedure [ Time Frame: 30-days post-procedure ]
  • The same 30-day composite of major adverse clinical events plus death and/or ipsilateral stroke between 31-days and 12-months post-procedure. [ Time Frame: Between day 31 and 12-months post-procedure. ]
  • · composite of major adverse clinical events including death, any stroke, and/or myocardial infarction at 30-days post-procedure;
  • · The same 30-day composite of major adverse clinical events plus death and/or ipsilateral stroke between 31-days and 12-months post-procedure.
Complete list of historical versions of study NCT00231270 on ClinicalTrials.gov Archive Site
  • successful stent deployment at the target lesion in a variety of carotid morphologies
  • successful filter deployment and retrieval
  • <30% residual stenosis determined by angiography immediately post-stent placement and post-dilatation
  • endovascular access site complications, such as the need for surgical repair or blood transfusion
  • surgical site complications, such as wound infection or hematoma, that prolong hospital stay, require incision and drainage, or need blood transfusion
  • patency (< 50% restenosis) of the Cordis Nitinol Stent as determined by carotid ultrasound imaging within 48 hours, at six months, and one, two and three years post-procedure
  • independent neurologic assessments at 24 + 12 hours, thirty days, six months, and one, two and three years post-procedure (in addition to stroke scales, the development of any cranial nerve deficits will be recorded) - persistent neurologic deficits
  • thirty (30)-day and six (6)-month evaluation for disabling stroke [ Time Frame: Day 30 and 6 months ]
  • six (6)-month, one (1)-year, two (2)-year and three (3)-year composite of major adverse clinical events including death and ipsilateral stroke [ Time Frame: 6 month and 1, 2, 3yr ]
  • safety assessment of the ANGIOGUARD XP Emboli Capture Guidewire Device
  • presence of trapped material as determined by the interventionalist's visual inspection of the ANGIOGUARD XP filter basket following recapture at the completion of the procedure
  • laboratory analysis of trapped material contained in the ANGIOGUARD XP filter basket
  • · successful stent deployment at the target lesion in a variety of carotid morphologies
  • · successful filter deployment and retrieval
  • · <30% residual stenosis determined by angiography immediately post-stent placement and post-dilatation
  • · endovascular access site complications, such as the need for surgical repair or blood transfusion
  • · surgical site complications, such as wound infection or hematoma, that prolong hospital stay, require incision and drainage, or need blood transfusion
  • · patency (< 50% restenosis) of the Cordis Nitinol Stent as determined by carotid ultrasound imaging within 48 hours, at six months, and one, two and three years post-procedure
  • · independent neurologic assessments at 24 + 12 hours, thirty days, six months, and one, two and three years post-procedure (in addition to stroke scales, the development of any cranial nerve deficits will be recorded) – persistent neurologic deficits
  • · thirty (30)-day and six (6)-month evaluation for disabling stroke
  • · six (6)-month, one (1)-year, two (2)-year and three (3)-year composite of major adverse clinical events including death and ipsilateral stroke
  • · safety assessment of the ANGIOGUARD XP Emboli Capture Guidewire Device
  • · presence of trapped material as determined by the interventionalist’s visual inspection of the ANGIOGUARD XP filter basket following recapture at the completion of the procedure
  • · laboratory analysis of trapped material contained in the ANGIOGUARD XP filter basket
Not Provided
Not Provided
 
Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy (SAPPHIRE)
Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy

The primary objective of this study is to compare the safety and effectiveness of the Cordis Nitinol Carotid Stent and Delivery Systems (5.5 F and 7 F) with the ANGIOGUARD XP distal protective device to CEA in the treatment of carotid artery disease in patients at increased risk for surgery.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Carotid Artery Disease
  • Device: Cordis Nitinol Stent
  • Device: PRECISE tapered stent
  • Device: ANGIOGUARD XP Emboli Capture Guidewire (ECGW)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1300
August 2005
Not Provided

Inclusion Criteria:

  1. The patient must be > 18 years of age.
  2. The patient has a 50% stenosis (as determined by ultrasound or angiogram) of the common or internal carotid artery and is clinically symptomatic; i.e., within the previous 180 days has experienced symptoms in the ipsilateral carotid artery distribution, defined as:

    • one or more TIAs, characterized by distinct focal neurologic dysfunction or monocular blindness with clearing of signs and symptoms within 24 hours, or
    • one or more completed strokes (as defined by this protocol) with persistence of symptoms or signs for more than 24 hours (the most recent event is used as the qualifying event), except as excluded below, with stenosis >50%, (as determined by ultrasound or angiogram) of the common or internal carotid artery, OR The patient must have a >80% diameter stenosis (as determined by ultrasound or angiogram) of the internal or common carotid artery without neurological symptoms.
  3. To be entered into the study, the patient must have one or more of the following conditions:

    • congestive heart failure (class III/IV) and/or known severe left ventricular dysfunction LVEF < 30%
    • open heart surgery within six weeks
    • recent MI (>24 hours and <4 weeks)
    • unstable angina (CCS class III/IV)
    • synchronous severe cardiac and carotid disease requiring open heart surgery and carotid revascularization
    • Age greater than 80 years as a single risk factor.

Exclusion Criteria:

  1. The patient is experiencing an acute ischemic neurologic stroke or has experienced a stroke within the past 48 hours.
  2. The patient has an intracranial mass lesion (i.e., abscess, tumor, or infection).
  3. The reference segment diameter (distal common carotid and internal carotid artery segment cephalic to the lesion) is less than 4mm or greater than 9mm by quantitative analysis. See Instructions For Use, for proper stent sizing. The exception to this would be with a lesion having >95% stenosis where the true diameter of the distal vessel can not be determined such as the case with a string sign or distal vessel collapse. In this case the judgment of the interventionalist will prevail with the intention not to oversize the stent to the distal vessel by more than 2mm.
  4. The patient has known peripheral vascular, supra-aortic or internal carotid artery tortuosity which preclude the use of catheter-based techniques if so randomized.
  5. The patient has any intracranial aneurysm (> 9 mm).
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00231270
P98-5201
Yes
Not Provided
Cordis Corporation
Not Provided
Not Provided
Cordis Corporation
July 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP